Disufenton

Summary

Disufenton (CHEMBL2111090) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 337.4 Da · C11H15NO7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111090
Name	Disufenton
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	151179
Molecular formula	C11H15NO7S2
Molecular weight	337.4
InChIKey	OVTCHWSLKGENKP-UHFFFAOYSA-N

SMILES: CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-]

IUPAC name: N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide

Parent form; salt/anhydrous children: CHEMBL2107334

Patent coverage: 21 distinct patent families (70 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).